



Ref: FOIA Reference 2023/24-747

Royal Stoke University Hospital  
Data, Security and Protection  
Newcastle Road  
Stoke-on-Trent  
Staffordshire  
ST4 6QG

Date: 14<sup>th</sup> March 2024

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear,

I am writing to acknowledge receipt of your email dated 6th February 2024 requesting information under the Freedom of Information Act (2000) regarding drug treatment.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 How many patients have been treated with the following drugs in the past 4 months:**

- **Atogepant (Aquipta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepiti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:*

- Atogepant (Aquipta) – any disease - 0
- Erenumab (Aimovig) - any disease - 226
- Eptinezumab (Vyepiti) – any disease - 0
- Fremanezumab (Ajovy) - any disease - 269
- Galcanezumab (Emgality) - any disease - 0
- Rimegepant (Vydura) – any disease - 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY - <5

**Q2** How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

A2 See below:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant	0	0
Erenumab	198	28
Eptinezumab	14	0
Fremanezumab	253	16
Galcanezumab	0	0
Rimegepant	0	3
Botulinum Toxin	219	0

**Q3** Does the Trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

A3 We do not routinely initiate a treatment pause for every patient. However, if the patient has low frequency episodic migraine (less than 8 headache days per month) then we will suggest a treatment pause with the patient.

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

Yours,



**Rachel Montinaro**  
Data Security and Protection Manager - Records